Portal de investigación
Immunogenicity of COVID-19 vaccines in lung cancer patients.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Estival A
- Franco F
- López-Vivanco G
- Saigí M
- Arasanz H
- Diz P
- Carcereny E
- García J
- Mosquera J
- Iruarrizaga E
- Majem M
- Bosch-Barrera J
- Mielgo-Rubio X
- Guirado M
- Lucía Gozálvez C
- Del Barrio A
- De Portugal T
- López-Martín A
- Serrano G
- Campos B
- Catot S
- Esteban B
- Martí-Ciriquian JL
- Del Barco E
- Calvo V
- Spanish Lung Cancer Group (SLGC/GECP)
Grupos
Abstract
OBJECTIVE: Patients with lung cancer are at increased risk of SARS-CoV-2 infection and severe complications from COVID-19, but information on the efficacy of anti-SARS-CoV-2 vaccine in these patients is scarce. We aimed at evaluating the safety and immunogenicity of COVID-19 vaccines in this population. PATIENTS AND METHODS: The prospective, nationwide SOLID substudy, enrolled adults with lung cancer who were fully vaccinated against COVID-19. Serum anti-SARS-CoV-2 IgG antibody levels were quantitatively assessed two weeks and six months after receipt of the last dose using a chemiluminescent microparticle immunoassay. Multivariate odds ratios for the association between demographic and clinical factors and seronegativity after vaccination were estimated. RESULTS: 1973 lung cancer patients were enrolled. Most patients had stage IV disease (66%) and were receiving active cancer treatment (82.7%). No significant differences were found in the probability of being seronegative for anti-SARS-CoV-2 IgG antibodies after full vaccination between patients who were receiving active cancer treatment and those who were not (p = 0.396). The administration of immunotherapy or oral targeted therapy and immunization with mRNA-1273 COVID-19 vaccine were factors independently associated with increased odds of being seropositive after vaccination. From all patients, 1405 received the second dose of vaccine and high levels of antibody titers were observed in 93.6% of patients two weeks after second dose. At six months, multivariate logistic regression analysis showed that performance status = 2 was independently associated with a higher probability of being seronegative after full vaccination with an OR 4.15. On the other hand, received chemotherapy or oral target therapy and vaccination with mRNA-1273 were a factor independently associated with lower odds of being seronegative after full vaccination with an OR 0.52, 0.37 and 0.34, respectively. CONCLUSIONS: Lung cancer patients can safely achieve a strong immune response against SARS-CoV-2 after full vaccination, regardless of the cancer treatment received. TRIAL REGISTRATION: NCT04407143.
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 0169-5002, 1872-8332
- Tipo:
- Article
- Páginas:
- 107323-107323
- PubMed:
- 37639820
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 1,399 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
LUNG CANCER ELSEVIER IRELAND LTD
Citas Recibidas en Web of Science: 8
Citas Recibidas en Scopus: 8
Documentos
- No hay documentos
Filiaciones
Keywords
- COVID-19; Immune response; Lung cancer; Neutralizing antibodies; SARS-CoV-2; Vaccine
Campos de Estudio
Cita
PROVENCIO M,Estival A,Franco F,López G,Saigí M,Arasanz H,Diz P,Carcereny E,García J,AGUADO C,Mosquera J,Iruarrizaga E,Majem M,Bosch J,Mielgo X,Guirado M,JUAN Ó,BLASCO A,Lucía C,Del Barrio A,De Portugal T,López A,Serrano G,Campos B,RUBIO J,Catot S,Esteban B,Martí JL,Del Barco E,Calvo V,Spanish Lung Cancer Group (. Immunogenicity of COVID-19 vaccines in lung cancer patients. Lung Cancer. 2023. 184. p. 107323-107323. IF:4,500. (1).